若生智能
Drug Database
FI

filgrastim (long-acting)

✓ Approved

Win Medica · CSF3R · 重组蛋白

什么是 filgrastim (long-acting)？

filgrastim (long-acting) 是一种重组蛋白，由Win Medica研发。该药已获批，用于治疗相关适应症，给药途径：Unknown。

药物档案

公司Win Medica
药物类别重组蛋白
分子靶点CSF3R
给药途径Unknown
状态Approved
来源： ClinicalTrials.gov, Win Medica

作用机制

分子靶点

filgrastim (long-acting) 作用于 1 个分子靶点：

CSF3Rcolony stimulating factor 3 receptor (CD114, GCSFR)
需要更深入的分析？Noah AI 可解释复杂机制并与同类药物比较。

治疗适应症

filgrastim (long-acting) 针对 1 个适应症，涉及 1 个治疗领域。

治疗领域疾病/病症分期
Blood and lymphatic system disordersBone marrow disorder✓ Approved

相关研究文献

PubMedVaccines2026-07-27

RSV Immunoprophylaxis in Infants and Children: Old Standards, New Agents and the Complexities Therein.

Paes Bosco A BA, Manzoni Paolo P, Fullarton John R JR, Rodgers-Gray Barry S BS et al.

Every year, respiratory syncytial virus (RSV) causes an estimated 33 million lower respiratory tract infections in children under five years of age, driving millions of hospitalizations worldwide and substantial mortality in developing countries. For 28 years, the monoclonal antibody (mAb) palivizumab has been the principal agent for RSV immunoprophylaxis, reducing hospitalization in defined high-risk groups through monthly intramuscular dosing. The recent approval of two second-generation long-acting mAbs, nirsevimab and clesrovimab, and maternal preF vaccine has fundamentally changed the RSV prevention landscape. In contrast to palivizumab, the long-acting mAbs offer single-dose seasonal protection across a broader infant population, enabling universal immunization programmes for the first time. In this review, we conjointly examine nirsevimab and clesrovimab across their mechanisms of action, pharmacokinetics, efficacy, safety and cost-effectiveness, using palivizumab as the reference standard. Cross-trial efficacy comparisons are complicated by differences in study populations and endpoint definitions; however, when these factors are considered, the available evidence suggests that all three agents offer broadly comparable protection against severe RSV disease. All three agents also demonstrate favourable and comparable tolerability profiles. Nirsevimab is now supported by a substantial body of real-world evidence confirming effectiveness in routine immunization programmes that closely align with registrational studies. Clesrovimab, as the newest agent, currently lacks real-world effectiveness, and both long-acting monoclonals require further confirmatory evidence in high-risk groups. Overall, existing data support that both monoclonals have equivalent efficacy and safety profiles as palivizumab, and choice should be based on cost-effectiveness and local availability, with consideration given to optimal integration of infant immunoprophylaxis alongside maternal RSV vaccination programmes.

PMID 42506593
阅读全文 →
PubMedJournal of pediatric and adolescent gynecology2026-07-27

When Barriers Are Removed: Increased Use of Long-Acting Reversible Contraceptives Among Adolescents in Primary Health Care Unit.

Souza Roseli B RB, Juliato Cássia R T CRT, Bahamondes Luis L

To evaluate the uptake of long-acting reversible contraceptive (LARC) methods among adolescents attending Primary Health Care (PHC) unit when methods were offered at no cost and accompanied by comprehensive counseling. We conducted an analytical cross-sectional study including adolescents aged 12-19 years who sought LARC initiation at a public Primary Health Care unit in Campinas, Brazil, between October 2024 and December 2025. Participants received standardized counseling and freely choose among the etonogestrel (ENG) implant, the 52-mg levonorgestrel-releasing intrauterine device (52 mg LNG-IUD), and the copper (Cu) IUD. Sociodemographic and reproductive history data were collected. Factors associated with method choice were analyzed using Poisson regression with robust variance. A total of 207 adolescents were included (median age 17 years). Most participants (82.1%) selected the ENG implant, while 16.9% chose the 52 mg LNG-IUD and 1.0% the Cu-IUD. IUD users were older and more likely to report previous pregnancy compared with implant users (p < 0.001). IUD insertion was considered easy in 82.9% of cases, with low complication rates and no insertion failures. Prior to enrollment, LARC use was uncommon, with most adolescents relying on short-acting methods. When provided with comprehensive counseling and free access within Primary Health Care unit, adolescents demonstrated high uptake of LARC methods, particularly the ENG implant. These findings support expanding LARC provision in public health services as a strategy to promote reproductive autonomy and reduce unintended adolescent pregnancy.

PMID 42503346
阅读全文 →
PubMedACS macro letters2026-07-27

Determining Preparation-Induced Differences in Local Forces Acting along Polymer Chains in Spin-Coated Films.

Fu Meirui M, Hertel Raphael R, Dajka Bence B, Walter Michael M et al.

We employed photoluminescence (PL) from mechanochromophores covalently linked into the backbone of a glassy polymer as optical force sensors ("optical springs") to resolve forces acting along polymer chains in spin-coated thin films. From the shift of the peak position of the PL spectrum, we deduced changes in the main force. Changes in the shape of the spectra were interpreted as alterations in populations of polymer chains experiencing lower and higher forces than the main force. Depending on the conditions of spin coating, expressed through a preparation parameter pev, we observed distinct changes in the corresponding PL spectra of the resulting polymer films, reflecting characteristic variations in the distribution of forces acting along polymer chains as a function of pev. Our results allowed to link the forces acting along individual polymer chains in spin-coated polymer films with macroscopically detected residual stresses, with the latter reflecting the combined and cooperative response of a large ensemble of polymer chains. Interestingly, residual stresses and the forces acting along individual polymer chains did not exhibit the same dependence on pev.

PMID 42503772
阅读全文 →
PubMedJournal of medical virology2026-07-27

HCV-Specific T-Cell Recovery After a Year of SVR Following DAA Therapy.

Pozniak Tetiana T, Sharaf Salma S, Gross Chloe C, Ebah Emade E et al.

Direct-acting antiviral (DAA) drugs lead to sustained virologic response (SVR) in almost all treated patients with chronic hepatitis C virus (HCV) infection. Despite this success, the long-term effects of HCV clearance by DAA therapy on T-cell-mediated antiviral immunity remain unclear, particularly concerning the restoration of immune function and its role in providing subsequent protection against reinfection. Our results demonstrated enhanced HCV-specific cytokine production by CD4+ T cells in vitro, particularly in the activated CD38+ and CD38+ HLADR+ subsets 1 year after DAA-mediated cure with increased frequencies of TNF-α+, IFNγ+TNF-α+, IL-2+, and IL-21+ cells. Notably, these subsets also exhibited reduced expressions of inhibitory markers, PD1 and TIGIT. Furthermore, reduced mitochondrial reactive oxygen species production and increased mitochondrial membrane potential were observed in CD38+ T helper cells, suggesting improved mitochondrial function. Significant reductions in serum IP-10, MIP-1β, and TNF-α levels were observed, indicating decreased systemic inflammation. These findings suggest that DAA-mediated HCV cure partially restores T helper cell function through reduced expression of inhibitory markers and improved mitochondrial activity in a subset of chronic HCV patients 1 year after SVR, which may potentially enhance immune protection and reduce the risk of reinfection.

PMID 42504457
阅读全文 →
PubMedAnnals of medicine2026-07-27

Liposomal bupivacaine versus ropivacaine for surgical site infiltration in lumbar fusion: a prospective randomized controlled trial.

Yue Feng F, Zhai Wenwen W, Lyu Yanhan Y, Qi Qiang Q et al.

Effective postoperative pain control after lumbar spine surgery remains challenging, and excessive opioid use is associated with adverse outcomes. Evidence comparing liposomal bupivacaine (LB) with conventional long-acting local anesthetics in spine surgery is limited. In this single-center, prospective, randomized, patient- and outcome assessor-blinded trial, adult undergoing one- or two-level posterior lumbar decompression and fusion were assigned (1:1) to surgical site infiltration with either LB (266 mg) plus 25 mg plain bupivacaine (LB group) or ropivacaine (R group). The primary outcome was 72 h cumulative opioid consumption (morphine milligram equivalents, MME). Secondary outcomes included time-profile opioid consumption, pain scores, rescue analgesia, safety, and functional recovery. A total of 202 patients were included in the modified intention-to-treat analysis. Cumulative MME within 72 h was significantly lower in the LB group compared with the R group [43.0 (37.0, 58.0) mg vs. 58.0 (46.0, 73.0) mg], corresponding to a 22% relative reduction (GMR 0.78, 95% CI 0.71-0.85; p < 0.001). The reduction was most pronounced during 8-24 h and 24-48 h postoperatively. Overall pain scores at rest and with movement, as well as 72-h pain AUC, were lower in the LB group. No significant between-group differences were observed in rescue analgesia, adverse events and functional recovery. In patients undergoing one- or two-level posterior lumbar decompression and fusion, surgical site infiltration with an LB-based combined regimen, compared with ropivacaine monotherapy, reduced 72-h opioid consumption and cumulative postoperative pain burden without an observed increase in adverse events or impairment of early functional recovery.

PMID 42504098
阅读全文 →
PubMedVaccines2026-07-27

Maternal Immunization Against Respiratory Syncytial Virus: An Integrative Review of Efficacy, Safety, and Implementation.

Almeida Isadora Rodrigues IR, de Vita Silva Marcela Fermoselle MF, de Brito Cavalcante Taline T, Alves de Britto Giovanna G et al.

Respiratory syncytial virus (RSV) is a leading cause of severe lower respiratory tract infection in young infants and accounts for substantial morbidity, hospitalization, and mortality worldwide, with the highest burden concentrated in the first months of life, when immunological and anatomical immaturity favors severe disease. Maternal vaccination has emerged as a strategy to bridge this window of vulnerability through the transplacental transfer of neutralizing antibodies. This integrative review synthesizes scientific articles published between 2022 and 2026, including systematic reviews, meta-analyses, narrative reviews, and position statements from national and international scientific societies, addressing the epidemiology, clinical manifestations, diagnosis, mechanism of action, efficacy, safety, and public health impact of maternal RSV immunization. The bivalent prefusion F protein vaccine (RSVpreF; Abrysvo®), administered as a single intramuscular dose between 32 and 36 weeks of gestation, induces maternal IgG that is transferred to the fetus and confers passive protection during the first six months of life. In the phase 3 MATISSE trial, vaccination demonstrated 81.8% efficacy against severe RSV lower respiratory tract infection within 90 days of birth and 69.4% within 180 days, alongside reductions in hospitalization. The safety profile was favorable, with predominantly mild and transient adverse events; a numerical imbalance in preterm birth remains under surveillance and underlies the precautionary gestational window. Maternal vaccination and long-acting monoclonal antibodies (nirsevimab) are best regarded as complementary rather than competing strategies. Current evidence supports maternal immunization as one of the most effective measures to reduce the burden of RSV disease in early infancy.

PMID 42506661
阅读全文 →

注册免费账户还可查看另外 9996 篇文献

免费注册查看全部文献 →

了解更多filgrastim (long-acting)